Insider Transactions in Q3 2024 at Day One Biopharmaceuticals, Inc. (DAWN)
Insider Transaction List (Q3 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 10
2024
|
Samuel C. Blackman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
30,000
-2.66%
|
$420,000
$14.22 P/Share
|
|
Aug 16
2024
|
Adam Dubow GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
3,202
-10.63%
|
$44,828
$14.0 P/Share
|
|
Aug 16
2024
|
Charles N York Ii COO, CFO AND SECRETARY |
SELL
Open market or private sale
|
Direct |
2,633
-1.12%
|
$36,862
$14.0 P/Share
|
|
Aug 16
2024
|
Samuel C. Blackman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
2,232
-0.2%
|
$31,248
$14.0 P/Share
|
|
Aug 16
2024
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
10,681
-9.74%
|
$149,534
$14.0 P/Share
|
|
Aug 15
2024
|
Adam Dubow GENERAL COUNSEL |
BUY
Exercise of conversion of derivative security
|
Direct |
8,399
+9.27%
|
-
|
|
Aug 15
2024
|
Charles N York Ii COO, CFO AND SECRETARY |
BUY
Exercise of conversion of derivative security
|
Direct |
10,250
+1.44%
|
-
|
|
Aug 15
2024
|
Samuel C. Blackman HEAD OF R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
8,686
+0.26%
|
-
|
|
Aug 15
2024
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
19,999
+5.98%
|
-
|
|
Jul 16
2024
|
Samuel C. Blackman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
20,000
-1.75%
|
$320,000
$16.01 P/Share
|
|
Jul 02
2024
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
BUY
Bona fide gift
|
Indirect |
241,912
+7.78%
|
-
|
|
Jul 02
2024
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
SELL
Bona fide gift
|
Indirect |
241,912
-23.03%
|
-
|